Hope in the Ocular Melanoma Journey
February 17, 2022Guest blog post by Samantha Buirski, ocular melanoma patient, advocate and member of the CURE OM Patient Steering Committee: Being part of a rare community is challenging. As humans we believe we are in control of our destinies and our future. When you …
The First FDA Approved Treatment for Metastatic Uveal Melanoma: What It Means for the OM Community
February 11, 2022On January 26, 2022, the U.S. Food and Drug Administration announced the approval of KIMMTRAK (tebentafusp-tebn), the first and only FDA-approved treatment for metastatic uveal melanoma, developed by Immunocore. The approval follows Phase III clinical …
Advocating Through Research Review Processes
February 11, 2022Guest blog post by Kristin R. McJunkins, Stage III melanoma survivor and advocate: In 2008 when I was 38 years old, I was diagnosed with Stage IIIa cutaneous melanoma. After two surgeries, which included some lymph node removal, it was determined that …
A Monumental First Step in Uveal Melanoma
February 9, 2022Guest blog post by Keith T. Flaherty, MD, Associate Professor of Medicine at Harvard Medical School, Director of Developmental Therapeutics at Massachusetts General Hospital Cancer Center and Co-Chair of the MRF’s CURE OM Scientific Steering Committee: …
Scientific Peer Review of Congressionally Directed Medical Research Programs’ Melanoma Research Program for the Department of Defense
January 21, 2022The MRF is proud to share the following press release from the Congressionally Directed Medical Research Program announcing MRF Board Chair (and melanoma survivor) Doug Brodman’s participation in the review of applications for a $30 million appropriati …
Recent Comments